Vitasora HealthASX:VHL EBITDA Margin % is -214.90% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Vitasora Health ranks worse than 93.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vitasora Health's EBITDA for the
six
months ended in Dec. 2025 was A$-4.95 Mil. Vitasora Health's Revenue for the
six
months ended in Dec. 2025 was A$2.30 Mil. Therefore, Vitasora Health's EBITDA margin for the quarter that ended in Dec. 2025 was -214.90%.
Vitasora Health (ASX:VHL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vitasora Health EBITDA Margin % Related Terms
Vitasora Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vitasora Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VHL vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Vitasora Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitasora Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Vitasora Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vitasora Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitasora Health (ASX:VHL) has a EBITDA Margin % of -214.90% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitasora Health and its competitors. According to the industry distribution chart, Vitasora Health ranks #627 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 93.9%.
Is Vitasora Health's EBITDA Margin % too high?
Vitasora Health's current EBITDA Margin % is -214.90%. Based on the distribution chart, Vitasora Health ranks #627 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Vitasora Health's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Vitasora Health ranks #627 out of 668 companies for EBITDA Margin %. This places Vitasora Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitasora Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitasora Health's current EBITDA Margin % is -214.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitasora Health stock overvalued right now?
Vitasora Health (ASX:VHL) has a current EBITDA Margin % of -214.90%. The current EBITDA Margin % is -214.90%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vitasora Health (ASX:VHL), the current EBITDA Margin % is -214.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitasora Health Ltd is engaged in healthcare technology and services, providing critical patient health tracking services to clinicians and healthcare teams. Through data-driven programs, clinical technology, and support tools, it enables healthcare professionals to extend the capacity of care beyond the clinic. The company operates in Australia and the USA, with the majority of its revenue coming from the USA. The United States reportable segment, through the acquisition of Access Telehealth and Orb Health, provides reportable segment activities such as a broader value proposition and solutions for managing the majority chronic disease states, including Cardiovascular, Diabetes, Chronic Obstructive Pulmonary Disease (COPD), and Obesity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VHL has been successfully added to your 